Scheriproct Ointment is used for the symptomatic management of non-infective anorectal conditions. This short-term topical application is typically indicated for the relief of local symptoms associated with internal or external haemorrhoids (piles), superficial anal fissures, and pruritus ani (anal itching). The medication aims to help mitigate discomfort by addressing localized issues such as inflammation, swelling, itching, and soreness in the affected area.

The primary benefit a patient may experience is support for localized symptom control and temporary comfort. The product is licensed for the management of these symptoms.

Quick Fact: Relief for Inflammation, Pain, and Itching

Official Eligibility Profile for Scheriproct Ointment

Regulatory agencies define strict eligibility criteria for the use of Scheriproct Ointment (Prednisolone Hexanoate/Cinchocaine Hydrochloride).

---

Contraindicated Populations

Use of the ointment is absolutely contraindicated in several specific populations, as explicitly stated in the regulatory label:

• Patients with hypersensitivity to either active ingredient or any excipient.
• Individuals with local viral infections (such as herpes, varicella, or vaccinia) in the treatment area.
• Patients with tuberculosis or syphilitic processes affecting the area to be treated.
• Women during the first trimester of pregnancy.

---

Restricted and Non-Recommended Use

Eligibility is limited for other specific groups:

• Children and Adolescents: Use is not recommended in individuals under 18 years of age due to a lack of established safety data and potential for systemic corticosteroid effects.
• Pregnancy and Lactation: Use is not recommended in later trimesters of pregnancy or while breastfeeding; the benefits must be carefully evaluated against the risks.
• Duration: For all eligible adults, use is restricted to the shortest possible duration (typically a maximum of 7 days) to limit systemic absorption.

Note: Scheriproct Ointment is generally indicated for short-term symptomatic use in the adult population, provided no contraindications are present.

Interactions with other medicines and products

The official interaction profile for Scheriproct Ointment is defined by two primary types of interaction: those with certain medicinal products and those related to physical products like latex.

Interactions with Medicinal Products

Co-treatment with strong inhibitors of the CYP3A enzyme system, such as ritonavir or other cobicistat-containing products, is expected to increase the systemic exposure of the corticosteroid component, prednisolone. This increase in exposure carries a higher risk of systemic corticosteroid-related side effects.

Interacting Product Category	Official Restriction/Condition
CYP3A Inhibitors (e.g., Cobicistat, Ritonavir)	Avoid combination unless the benefit outweighs the increased risk; patients must be monitored for systemic corticosteroid effects if co-administered.

Interactions with Other Products

The excipients contained in Scheriproct Ointment, which include various castor oil components, may damage latex products. As a result, the effectiveness of latex-containing items, such as condoms, may be reduced when used concomitantly with the ointment. It is important to note this physical interaction to ensure the intended protective function of the latex product is not compromised.

The pharmacological activity of Scheriproct Ointment is defined by the complementary action of two distinct components: a steroid pro-drug that alters genomic signaling and an anesthetic agent that blocks peripheral sensory conduction.

Genomic Modulation of the Inflammatory Cascade

This domain centers on Prednisolone Caproate, a pro-drug converted to prednisolone, which acts as an agonist at the Glucocorticoid Receptor. This initiates a genomic signaling cascade, ultimately inhibiting the enzyme Phospholipase A2 ( PLA2). This molecular mechanism reduces the synthesis of pro-inflammatory mediators, supporting the attenuation of oedema (fluid accumulation).

Direct Blockade of Sensory Nerve Signal Transmission

This domain involves Cinchocaine Hydrochloride, which physically targets Voltage-Gated Sodium Channels ( Navs) on peripheral nerve fibers. By stabilizing these channels in their inactive state, the molecule blocks the influx of Na^+ ions required for depolarization. This rapid, non-genomic intervention halts the electrical transmission of nociceptive and pruritic sensory signals.

Mechanistic Synergy and Onset Dynamics

The combination ensures functional synergy: the channel blockade provides rapid peripheral sensory blockade, while the slower genomic modulation alters activity within the underlying biological pathways. This complementary action modulates both the peripheral sensory signaling and the ongoing tissue hyper-reactivity.

The administration of Scheriproct Ointment involves the rectal route and a standardized dosage regimen.

Official Dosage and Administration

Administration Element	Details
Route of Administration	Rectal (External and internal application)
Initial Dosing (Day 1)	Apply up to three or four times to obtain quick relief.
Standard Dosing	Apply in a thin layer twice daily, unless otherwise prescribed.
External Quantity	A small quantity (about the size of a pea)
Internal Quantity	One applicator full

Procedural Requirements and Duration

Preparation Steps:

• The anal region must be gently but thoroughly washed and dried before using the ointment.
• Application is best done after a bowel movement (defaecation).
• Always wash hands before and after applying the ointment.

Application Method:

• External: Smear the specified quantity onto the finger and spread it gently over the skin around and just inside the anus. Do not rub it in.
• Internal (Intra-rectal): Screw the provided applicator onto the tube, fill the applicator with ointment (one dose), and insert it carefully until the whole length is inside. Gently squeeze the tube while withdrawing the applicator. If the area is severely painful, the ointment can be applied internally with a finger instead of the applicator.

Duration and Schedule:

• Treatment duration should not exceed four weeks.
• To prevent a recurrence, treatment should continue once a day for at least one week after the physical symptoms have completely cleared.
• The use of a waterproof dressing over the treated area is explicitly forbidden.

Research evidence / Overview of studies

Evidence in Symptom Management

Research, primarily within controlled studies, explored the combination of prednisolone hexanoate (a corticosteroid) and cinchocaine hydrochloride (a local anaesthetic) for the management of haemorrhoidal symptoms, anal fissures, and proctitis. These studies focused on the reduction of inflammation, swelling, itching, and associated pain. The primary measured outcomes included changes in symptom severity scores and the time until a predefined change in symptoms was recorded.

Comparative Findings and Duration

Clinical data consistently indicate that this combination is generally reserved for short-term use, typically for a duration not exceeding seven days. This specific limitation is primarily due to the prednisolone component, a topical corticosteroid, and the associated risk of local adverse effects such as skin thinning when used for prolonged periods.

In one study examining treatment outcomes, both the ointment and suppository formulations were assessed, achieving broad control of symptoms by the third week of therapy. Data regarding the speed of effect suggested that suppositories may be associated with marginally greater symptomatic improvement in the very early stages of treatment.

Safety Profile Summary

Observed adverse events in clinical use are generally mild and may include temporary skin reactions at the application site. Allergic skin reactions have been reported in rare cases. Patients in these studies were monitored for specific steroid-related concerns, including the risk of localized skin atrophy or adrenal gland activity reduction if the product were applied extensively over a long duration.

Participants with specific conditions, such as viral, primary bacterial, or fungal infections in the treatment area, are typically excluded from using this product, as its components do not treat the underlying infection.

Key Studies & References Preparations containing a corticosteroid for haemorrhoids (piles)

Common questions about Scheriproct Ointment (FAQ)

Q: How quickly does Scheriproct Ointment usually start to relieve symptoms?

A: Official product information notes that the medicine contains the local anaesthetic component, Cinchocaine Hydrochloride. This ingredient is included to provide temporary relief from pain and itching.

As part of the suggested regimen, regulatory documents mention that application may be more frequent on the first day to achieve this quick relief.

---

Q: Can Scheriproct Ointment cause irritation or a burning feeling?

A: Official safety information indicates that adverse reactions associated with the ointment are primarily local skin reactions.

Excipients, which are non-active ingredients like castor oil, may also be associated with skin reactions at the site of application. The safety information notes that local skin reactions, if persistent, are typically addressed by a healthcare professional.

---

Q: Is it common to have skin thinning after using this ointment?

A: The thinning of the skin, known as atrophy, is a documented risk associated with the corticosteroid component of the medicine.

Official safety information specifies this risk is generally tied to long-term continuous use, which is the rationale for regulatory duration limits on treatment.

---

Q: What is the role of Cinchocaine in the ointment?

A: According to the official product information, Cinchocaine Hydrochloride is a local anaesthetic.

Its purpose is to provide quick, temporary relief from physical symptoms, specifically pain and itching associated with the condition being treated.

---

Q: Can using too much Scheriproct Ointment cause problems?

A: Accidental use of an excessive amount is stated in regulatory information as unlikely to be dangerous, but the prolonged use or application of very large quantities may increase the risk of side effects.

The regulatory warning is primarily focused on the potential for increased absorption of the corticosteroid ingredient, which can lead to systemic effects like skin thinning or adrenal suppression.

---

Q: Can I use Scheriproct Ointment if I'm using other topical treatments?

A: Official regulatory documents advise patients to inform their prescribing doctor if they are currently using other creams, ointments, or suppositories in the same treatment area.

---

Q: Does Scheriproct Ointment help with internal hemorrhoids or just external ones?

A: Official instructions indicate that the ointment can be used for both external and internal haemorrhoids.

The medicine is formulated to be applied externally around the anus or inserted into the rectum using the provided applicator for internal use.

---

Q: What if I accidentally swallow a small amount of the ointment?

A: According to the patient information leaflet, the accidental swallowing of a small amount of the ointment is considered unlikely to be dangerous.

However, if a larger quantity is swallowed or if the patient is concerned, seeking advice from a healthcare professional or pharmacist is the documented recommendation.

---

Q: Can I use Scheriproct Ointment while drinking alcohol?

A: The official safety and interaction profile of the medicine, which lists known interactions with other medicinal products and physical items like latex, does not list an interaction with alcohol.

---

Q: What happens if I stop using the ointment suddenly?

A: Official guidance on duration advises continuing application once a day for at least one week after physical symptoms have completely cleared.

Abruptly stopping the treatment after a prolonged period of continuous use is documented as potentially being associated with a return of symptoms or a rebound effect, which is the rationale for the specified duration limits.

---

Q: Does Scheriproct Ointment contain lidocaine or any numbing agents?

A: The ointment does contain a numbing agent, which is the active ingredient Cinchocaine Hydrochloride, a type of local anaesthetic.

However, regulatory documents confirm that the medicine does not list the anaesthetic Lidocaine as one of its active ingredients.

---

Q: What are the most common reasons a doctor prescribes this ointment?

A: Official regulatory documents indicate that the medicine is prescribed for the relief of inflammation, swelling, itching, and soreness associated with piles (haemorrhoids).

It is also indicated for the relief of itching of the anus (anal pruritus).

---

Q: Do studies support the use of Scheriproct Ointment for the intended condition?

A: Clinical evidence and research have been used to examine the combination of the anti-inflammatory component (corticosteroid) and the anaesthetic component.

These studies focus on the product's ability to reduce inflammation, swelling, and associated pain and itching in haemorrhoidal symptoms.

---

Q: Is it normal for the symptoms to return after stopping treatment?

A: Regulatory guidance advises that treatment should continue once a day for at least one week after the physical symptoms have completely cleared.

This is intended to help reduce the possibility of symptoms returning soon after the initial recovery.

---

Q: Can Scheriproct Ointment be used on other parts of the body?

A: The official classification and indications for this product define it as a Rectal Ointment.

Therefore, its use is intended and restricted to the anal/rectal region as described in the application instructions.

---

Q: Can Scheriproct Ointment be used for other types of itching?

A: The medicine’s officially labelled indications are specific to the relief of itching associated with piles (haemorrhoids) and general anal itching.

Its use for other types of itching outside of these specific indications is not covered by the regulatory scope.

---

Q: Can older adults use Scheriproct Ointment without any extra precautions?

A: Regulatory documents explicitly state that no data is available regarding the use of Scheriproct Ointment in the elderly population.

---

Q: Does using Scheriproct Ointment affect a blood test?

A: Official safety information explicitly states that no data is available regarding the effects of the ointment on standard laboratory tests, such as blood tests.

Any potential interference would not be documented in the product information.

---

Q: What should I do if I forget to apply the ointment?

A: If a dose of the ointment is forgotten, the official instruction is not to use a double dose to make up for the missed application.

The patient information advises continuing with the regular prescribed schedule.

---

Q: Is it normal to feel relief right after application?

A: The medicine is specifically formulated to provide rapid relief from local pain and itching due to the inclusion of a local anaesthetic component.

Therefore, the expectation of feeling relief shortly after application is consistent with the product's design.

How to Store and Dispose of Scheriproct Ointment

Official regulatory documents define specific conditions for the storage and disposal of Scheriproct Ointment to maintain its quality and ensure environmental safety.

Storage Requirements

The ointment must be stored in its original container at a temperature not exceeding 25, C. The tube should be kept tightly closed when not in use. After the tube is initially opened, the product must be discarded after 3 months.

Child Safety and Disposal

It is mandatory to keep this medicine out of the sight and reach of children. When disposing of unused or expired ointment, do not use household waste or wastewater. Instead, return the product to a pharmacist for proper pharmaceutical waste disposal.